OCT 24, 2019 9:43 PM PDT

Patients can Self-Inject Easily Using an Integrated Pre-Filled Syringe and Autoinjector

WRITTEN BY: Nupur Srivastava

The patients suffering from chronic disease require a regular dose of medicines, either orally or as injections. The patients prefer the self-injection method as it is easy to use, cost-effective, and prevents a monthly visit to the specialists.

Because chronic diseases require repeated dosing of medicines, the market for self-injections grew at over 22% per year towards nearly $80 billion by 2022.

“This move towards injection of biologics at home is a clear trend in our society and our industry, and it presents a clear challenge for device developers,” says John A. Merhige, Chief Commercial Officer, Credence MedSystems, Inc.

Video courtesy: Dove Medical Press 

Becton, Dickinson, and Company (BD) is a global leader in medical technology and self-injection systems. BD announced the launch of Intevia at Parental Drug Association’s (PDA) 2019 Universe of Pre-Filled Syringes and Injection Devices conference held in Gothenburg, Sweden. BD Intevia is a 1mL two-step integrated platform device that combines both an autoinjector and a pre-fillable syringe in one system (Image 1 and a Video). The system favorably optimizes patient self-injections with high-viscous drugs and therapies. 

Peter Nolan, Worldwide President, BD Medical - Pharmaceutical Systems, said: “BD Intevia is a new generation of BD autoinjectors that will help drug manufacturers seamlessly enhance drug delivery experience.” “For the patient, the platform technology is designed to promote patient ease of use when self-injecting, and it is supported by BD’s worldwide clinical injection expertise harnessing the latest research in drug delivery technology,” he added.

Image 1: The features of BD Intevia

The latest validation study participants highly rated BD Intevia autoinjector-prefill syringe and switching to the integrated disposable system for key product attributes as:

  • Overall acceptance, and
  • Confidence to control the start of injection.

Source: MarketSearchEngine, BD Intevia

About the Author
You May Also Like
AUG 13, 2020
Clinical & Molecular DX
A Call for Bigger, Better Studies on AI Breast Cancer Diagnostics
AUG 13, 2020
A Call for Bigger, Better Studies on AI Breast Cancer Diagnostics
A staggering 1 in 8 women in the U.S. will develop an aggressive form of breast cancer in their lifetime, making it the ...
AUG 16, 2020
Microbiology
Newly Discovered Gut Enzyme Could Function as Disease Biomarker
AUG 16, 2020
Newly Discovered Gut Enzyme Could Function as Disease Biomarker
Bacteria in the gut have a powerful influence on our health, in part because all of those microbes have genes of their o ...
SEP 07, 2020
Clinical & Molecular DX
Spot the Robodog Measures COVID Patients' Vitals
SEP 07, 2020
Spot the Robodog Measures COVID Patients' Vitals
Hospital staff caring for COVID-19 patients face the greatest risk of exposure to the virus. A new dog-like robot design ...
NOV 05, 2020
Clinical & Molecular DX
Digging DEEP into Metabolomic Space
NOV 05, 2020
Digging DEEP into Metabolomic Space
Metabolomics is an umbrella term encompassing lipidomics and the study of smaller polar metabolites.  As such, more ...
NOV 03, 2020
Clinical & Molecular DX
"Hello? It's Me, the Coronavirus."
NOV 03, 2020
"Hello? It's Me, the Coronavirus."
Researchers at MIT have discovered an unlikely way of discerning those with COVID-19 from healthy individuals — si ...
NOV 12, 2020
Clinical & Molecular DX
Study Shows 1 in 5 COVID Tests Are False Positives
NOV 12, 2020
Study Shows 1 in 5 COVID Tests Are False Positives
  A study published in The BMJ has brought to light that the rapid finger-prick COVID-19 test may not be quite as r ...
Loading Comments...